Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with pancreatic cancer confirmed through a tissue or cell sample test
- People whose cancer has been classified as "borderline resectable" according to a specific international medical definition from 2017 (confirm with trial site)
- People whose cancer has not spread to distant parts of the body
- People whose recent blood test results fall within certain required ranges for white blood cells, platelets, liver function, and kidney function (confirm with trial site for specific values)
- People aged 18 or older
- People who score 70 or above on a standard health and activity scale called the Karnofsky index (confirm with trial site)
- People whose cancer has not grown into the stomach or the first part of the small intestine (duodenum)
- People who are fully informed of their diagnosis and are able to give written consent to participate
- Women who could become pregnant must be using adequate contraception and must not be breastfeeding
- People who have signed a consent form before the study begins
Who may not be able to join:
- People whose pancreatic tumour is not of the type that develops in the exocrine (outer secreting) part of the pancreas
- People with serious medical or psychiatric conditions that make radiation therapy, chemotherapy, or surgery unsuitable for them
- People whose cancer has already spread to distant parts of the body
- People who are pregnant, or who are not willing to use adequate contraception
- People who are breastfeeding and not willing to stop
- Men who could father a child and are not willing to use effective contraception
- People who have had a known allergic or hypersensitivity reaction to any of the treatments used in this study
- People who have previously been diagnosed with another type of cancer that has a worse outlook than pancreatic cancer in this context (confirm with trial site)
- People who have a metal implant or other condition that would prevent clear medical imaging needed to plan treatment
- People with local conditions in the treatment area that make radiation therapy unsuitable, such as an active infection nearby
- People who have had radiation therapy to the abdomen in the past
- People who have already received systemic (whole-body) treatment for pancreatic cancer
- People with a known allergy or sensitivity to paclitaxel, albumin-bound paclitaxel (nab-paclitaxel), gemcitabine, or any ingredients in these chemotherapy medicines
- People with severely reduced liver function
- People whose neutrophil count (a type of white blood cell) is below a required level at the start of the study
- People who already have moderate or severe nerve damage affecting sensation or movement (Grade 2 or higher neuropathy)
- People who do not wish to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Piero Fossati, M.D., EBG MedAustron GmbH
Phone: +43 664 80878
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Toxicity - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; Perioperative Mortality and Complications
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.